FLT3 and acute myeloid leukemia: In summary, here we report the final analysis of the prospective randomized phase II HOVON 155 trial, comparing a 10-day decitabine schedule with or without midostaurin, in unfit newly diagnosed FLT3 mutation agnostic AML patients.